What happened with PRPO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Physicians send patients’ blood and biopsy samples to Precipio, Inc.’s laboratories, which analyze them and return pathology reports, primarily for blood cancers. These testing services account for most of its revenue. Private insurers and Medicare pay most of the testing bills, so insurance coverage and reimbursement rates directly affect what Precipio earns.
A smaller business sells diagnostic products to other clinical laboratories, allowing those customers to perform testing themselves. These include HemeScreen assay panels and IV-Cell cell-culture media. Laboratories buy the products directly or through distributors and pay for them rather than relying on Precipio to collect insurance reimbursement. Precipio also uses its clinical laboratories to develop and validate products.
One customer accounts for a substantial share of total revenue. The laboratories must maintain CLIA certification, the U.S. certification required to operate clinical testing laboratories. Some products carry research-use-only labeling; if the FDA treats them as diagnostic medical devices, Precipio may need authorization before marketing them.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
NeoGenomics competes with Precipio for cancer testing and pathology interpretation ordered by oncology practices, hospitals and laboratories. Its services let those customers outsource testing or interpretation without adding laboratory equipment or staff, making its community oncology business worth watching for Precipio’s service revenue.
Labcorp competes with Precipio for physician-referred patient testing paid for by insurers and government programs. Its routine and specialty testing division, Dx, is the business to watch for this overlap, rather than its central laboratory and early-development services.
Quest Diagnostics competes for the clinical referrals that bring Precipio specialized pathology revenue, offering advanced and less-common tests that can require more complex analysis. Watch its Advanced Diagnostics testing business: certain tests across five clinical areas generated more than $1 billion in revenue in 2025, with double-digit growth.
Guardant Health competes with Precipio for clinical cancer testing, but focuses on liquid biopsy while Precipio mainly provides blood-cancer pathology services; both bill Medicare and private insurers for qualifying tests. Guardant’s oncology testing revenue is the closer comparison for Precipio, rather than its screening or biopharma and data revenue.
QIAGEN competes with Precipio’s HemeScreen for laboratories’ spending on products that detect and interpret molecular information from samples. Its consumables and related revenue is the line to watch: laboratories buy these supplies as part of workflows combining testing materials, instruments and analysis software.
Bio-Rad competes with Precipio’s HemeScreen for clinical laboratories’ purchases of molecular testing products. Precipio names Bio-Rad among providers of both single-gene assays and broader sequencing systems and assays, so its competing testing products matter more here than its company-wide sales.
Illumina sells sequencing equipment and reagents that clinical laboratories can choose instead of Precipio’s targeted HemeScreen panels. Watch its offerings for clinical molecular testing: Precipio pitches HemeScreen’s four-to-seven-gene panels, run on one relatively inexpensive RT-PCR machine, as a simpler alternative to broad sequencing panels.
NeoGenomics, Inc. earningsNEO
NeoGenomics' report will show how demand for outsourced cancer testing is changing among oncology practices and laboratories, the same market where Precipio seeks pathology-service referrals.
Focus on NeoGenomics' oncology testing revenue alongside any reported change in testing activity or business mix. Growth in both would point to supported demand for outsourced cancer testing, but also a resilient competitor for Precipio; weakness in both would suggest a harder market for Precipio's services, though this report alone cannot tell whether demand fell or a competitor won the work.
Bio-Rad Laboratories, Inc. earningsBIO
Bio-Rad's report can show whether clinical laboratories are buying molecular-testing products that compete with Precipio's HemeScreen for their budgets.
Look at Bio-Rad's reported sales for molecular-testing products, not just company-wide revenue. Stronger sales would show that laboratories are still spending in this market, while giving HemeScreen more competition from alternatives; weaker sales could ease that competitive pressure, but would not establish that laboratories will switch to Precipio.
Precipio, Inc. earningsThis company
Precipio's report will show whether revenue and gross profit from pathology cases continue to support the laboratory's operations.
Read pathology case volume beside service revenue, then check gross profit and cash from operations. More cases with revenue keeping pace and gross profit holding up would show that added testing is helping the lab spread fixed costs; weaker cases or revenue, or gross profit and operating cash that fail to keep up, would show growth is not yet easing funding pressure.
